ProMIS Neurosciences, Inc. Annual report [Section 13 and 15(d), not S-K Item 405]

Annual report [Section 13 and 15(d), not S-K Item 405]

WARRANTS

WARRANTS

12 Months Ended

Dec. 31, 2025

7.WARRANTS

As of December 31, 2025, outstanding Common Share warrants and exercise prices related to unit offerings are as follows:


Exercise		Number of
Price $		Warrants	Expiry date
US$50.50		314,170	January 2026
US$315.00		20,948	August 2026
US$240.00		5,868	August 2026
US$50.50		314,170	January 2027
US$187.50		13,831	April 2028
US$152.50		2,767	April 2028
US$43.75		449,084	February 2029
US$62.50		314,170	July 2029
US$31.25		1,129,324	July 2030
US$0.25		74,673	None
		2,639,005

During the year ended December 31, 2025, 51,197 pre-funded warrants, including 39,389 issued in the July 2025 RD Offering, were exercised for gross proceeds of $3,050. Refer to Note 6 for discussion on the discounted exercise of 336,449 July 2024 PIPE warrants on July 22, 2025, discounted exercise of 416,436 July 2024 PIPE warrants on July 28, 2025, issuance of 504,673 new warrants in the July 22, 2025 PIPE, and issuance of 624,654 new warrants in the July 28, 2025 PIPE. During the year ended December 31, 2025, 11,184 warrants expired without being exercised.

During the year ended December 31, 2024, 16,319 warrants expired without being exercised, and 112,150 pre-funded warrants were exercised for an equivalent number of common shares for net proceeds of $28,038.